762.18
price down icon1.23%   -9.53
after-market Handel nachbörslich: 762.56 0.38 +0.05%
loading
Schlusskurs vom Vortag:
$771.71
Offen:
$768.17
24-Stunden-Volumen:
2.99M
Relative Volume:
0.78
Marktkapitalisierung:
$722.35B
Einnahmen:
$49.00B
Nettoeinkommen (Verlust:
$11.11B
KGV:
62.02
EPS:
12.29
Netto-Cashflow:
$-1.27B
1W Leistung:
-4.65%
1M Leistung:
-0.07%
6M Leistung:
+2.67%
1J Leistung:
-11.11%
1-Tages-Spanne:
Value
$760.50
$772.00
1-Wochen-Bereich:
Value
$760.02
$805.42
52-Wochen-Spanne:
Value
$677.09
$972.53

Lilly Eli Co Stock (LLY) Company Profile

Name
Firmenname
Lilly Eli Co
Name
Telefon
(317) 276-2000
Name
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Mitarbeiter
47,000
Name
Twitter
@LillyPad
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
LLY's Discussions on Twitter

Vergleichen Sie LLY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.18 717.60B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
164.36 377.32B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
184.85 338.30B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
114.14 234.32B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.92 306.33B 43.59B 15.04B 10.74B 3.3766

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-05 Herabstufung Erste Group Buy → Hold
2025-04-28 Herabstufung HSBC Securities Buy → Reduce
2025-04-22 Eingeleitet Cantor Fitzgerald Overweight
2024-12-10 Fortgesetzt BofA Securities Buy
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-10-17 Eingeleitet Bernstein Outperform
2024-09-13 Fortgesetzt Citigroup Buy
2024-08-12 Hochstufung Deutsche Bank Hold → Buy
2024-02-21 Herabstufung DZ Bank Buy → Hold
2024-02-16 Bestätigt Morgan Stanley Overweight
2023-12-21 Herabstufung Daiwa Securities Buy → Outperform
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-10-20 Fortgesetzt UBS Buy
2023-08-09 Hochstufung Jefferies Hold → Buy
2023-07-26 Bestätigt Citigroup Buy
2023-07-14 Eingeleitet HSBC Securities Buy
2023-05-24 Bestätigt BofA Securities Buy
2023-05-24 Bestätigt UBS Buy
2023-03-13 Hochstufung Wells Fargo Equal Weight → Overweight
2023-03-06 Eingeleitet Jefferies Hold
2023-02-15 Herabstufung Societe Generale Hold → Sell
2022-11-18 Eingeleitet Credit Suisse Outperform
2022-09-22 Hochstufung UBS Neutral → Buy
2022-05-23 Eingeleitet SVB Leerink Outperform
2022-04-06 Fortgesetzt Morgan Stanley Overweight
2022-03-10 Eingeleitet Daiwa Securities Outperform
2022-01-21 Hochstufung DZ Bank Hold → Buy
2022-01-03 Bestätigt Bernstein Mkt Perform
2021-12-17 Eingeleitet Goldman Neutral
2021-12-16 Bestätigt BMO Capital Markets Outperform
2021-12-16 Bestätigt BofA Securities Buy
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-10-11 Hochstufung Berenberg Hold → Buy
2021-09-29 Hochstufung Citigroup Neutral → Buy
2021-08-05 Hochstufung DZ Bank Hold → Buy
2021-07-27 Fortgesetzt Truist Buy
2021-06-24 Bestätigt Cantor Fitzgerald Overweight
2021-01-19 Hochstufung Mizuho Neutral → Buy
2020-12-10 Hochstufung Wolfe Research Peer Perform → Outperform
2020-11-10 Fortgesetzt Bernstein Mkt Perform
2020-09-29 Eingeleitet Berenberg Hold
2020-09-03 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-06-16 Hochstufung Guggenheim Neutral → Buy
2020-04-21 Herabstufung UBS Buy → Neutral
2020-04-09 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-02-06 Eingeleitet Mizuho Neutral
2019-12-18 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-05-28 Eingeleitet Goldman Buy
2019-04-24 Hochstufung Edward Jones Hold → Buy
2019-04-11 Herabstufung Guggenheim Buy → Neutral
2019-03-12 Eingeleitet JP Morgan Overweight
2019-01-23 Eingeleitet UBS Buy
2018-11-26 Herabstufung Citigroup Buy → Neutral
2018-10-31 Hochstufung Credit Suisse Underperform → Neutral
2018-10-09 Eingeleitet Guggenheim Buy
2018-10-01 Bestätigt SunTrust Buy
2018-09-26 Fortgesetzt JP Morgan Overweight
Alle ansehen

Lilly Eli Co Aktie (LLY) Neueste Nachrichten

pulisher
11:48 AM

Eli Lilly’s Strategic Advantage in GLP-1RAs and Alzheimer’s Markets Fuels Buy Rating - TipRanks

11:48 AM
pulisher
10:00 AM

Eli Lilly: Competition Melts Away (NYSE:LLY) - Seeking Alpha

10:00 AM
pulisher
08:15 AM

2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade - The Motley Fool

08:15 AM
pulisher
Jul 20, 2025

Bernstein Remains Bullish on Eli Lilly and Company (LLY) With an $1,100 PT - Insider Monkey

Jul 20, 2025
pulisher
Jul 19, 2025

Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com

Jul 19, 2025
pulisher
Jul 18, 2025

Why Eli Lilly (LLY) is Emerging as a Dividend Growth Leader in Pharma for 2025 - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly and Company - Lifespan Research Institute

Jul 18, 2025
pulisher
Jul 18, 2025

Is Eli Lilly Stock A Buy On A Fresh Bout Of Alzheimer's News? - Investor's Business Daily

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Innovative Study on Bimagrumab and Tirzepatide: Market Implications - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s New Study on LY4050784: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s LUCENT 3 Study: A Promising Step for Ulcerative Colitis Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s KRAS Inhibitor Study: A Potential Game-Changer in Cancer Treatment? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Lepodisiran Study: A Step Forward in Liver Function Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Weight Management Study: A Potential Game-Changer in Obesity Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Promising Phase 1 Study on LY4101174: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s New Cancer Study: A Potential Game-Changer? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly & Co: Analyst Bullish on Diabetes Segment and Oncology Franchise Amid Competitive Pressures. - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly & Co: Promising Growth Prospects and Strategic Positioning Amid Competitive Pressures - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs? - The Motley Fool

Jul 18, 2025
pulisher
Jul 17, 2025

Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers By Investing.com - Investing.com India

Jul 17, 2025
pulisher
Jul 17, 2025

Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today? - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Senators reveal how much Lilly, Pfizer paid telehealth companies - statnews.com

Jul 17, 2025
pulisher
Jul 17, 2025

LLY Stock Quote Price and Forecast - CNN

Jul 17, 2025
pulisher
Jul 16, 2025

Eli Lilly Bets Big On Obesity And Diabetes Drugs - Finimize

Jul 16, 2025
pulisher
Jul 16, 2025

Jim Cramer on Eli Lilly: “How Can You Leave This One Right Here?” - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

ELI LILLY AND COMPANY (LLY) - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound - CNBC

Jul 16, 2025
pulisher
Jul 16, 2025

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga

Jul 16, 2025
pulisher
Jul 16, 2025

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Health Canada Expands Eli Lilly's Omvoh Indication to Crohn's, Approves Citrate-Free Formula - MarketScreener

Jul 16, 2025
pulisher
Jul 15, 2025

Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly’s Weight-Loss Drug Faces New Competition from China - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly Foundation provides $5.5 million grant for STEM education initiative at IPS - Fox 59

Jul 15, 2025
pulisher
Jul 15, 2025

The Zacks Analyst Blog Highlights Lilly, Netflix, GE Aerospace, Willis Lease and Flanigan's Enterprises - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly: Still Too Pricey To Buy (NYSE:LLY) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly (LLY) Gains Health Canada Approval for Omvoh in Crohn's Disease Treatment - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly’s Obesity Pill For The Masses Could Flip The $150 Billion Market on Its Head! - Smartkarma

Jul 15, 2025
pulisher
Jul 14, 2025

Top Research Reports for Eli Lilly, Netflix & GE Aerospace - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

Eli Lilly (LLY) Expects Results from Weight-Loss Pill Trial by Sept. 30 - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Eli Lilly’s Weight Management Study: A Potential Game-Changer? - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Eli Lilly’s New Study on SGLT2 Inhibitors: A Potential Game-Changer for CKD Anemia Management - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (July 2025) - 24/7 Wall St.

Jul 14, 2025
pulisher
Jul 14, 2025

Eli Lilly and Company (LLY) Stock Analysis: Exploring a Potential 20% Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews

Jul 14, 2025
pulisher
Jul 13, 2025

Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into Indias Weigh-Loss Drug Sector - NDTV Profit

Jul 13, 2025
pulisher
Jul 12, 2025

Eli Lilly and Company (LLY): I Would “Love” If Trump Praised The Company, Says Jim Cramer - Insider Monkey

Jul 12, 2025
pulisher
Jul 11, 2025

Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth - Yahoo Finance

Jul 11, 2025
pulisher
Jul 11, 2025

Eli Lilly Surges Ahead: JPMorgan Sees $1,100 Price Target on Obesity Drug Boom - Yahoo

Jul 11, 2025

Finanzdaten der Lilly Eli Co-Aktie (LLY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general JNJ
$164.36
price up icon 0.40%
$184.85
price down icon 2.33%
drug_manufacturers_general NVS
$114.14
price down icon 0.10%
drug_manufacturers_general NVO
$64.92
price up icon 0.95%
drug_manufacturers_general MRK
$79.31
price down icon 0.81%
Kapitalisierung:     |  Volumen (24h):